Targeting the vascular RhoA-Rho-kinase signaling pathway in hypertension

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 3, 2005, Pages 193-199

  Teixeira, Cleber E ^a   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM SENSITIZER; CANDESARTAN; CARVEDILOL; FASUDIL; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; H 1152; LISINOPRIL; NEBIVOLOL; NISOLDIPINE; NITROPRUSSIDE SODIUM; RGS2 PROTEIN; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VALSARTAN;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; BRAIN VASOSPASM; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY SPASM; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; IN VITRO STUDY; LETHARGY; MUSCLE CONTRACTION; NEWBORN DEATH; NONHUMAN; PATHOGENESIS; PERIPHERAL EDEMA; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SENSITIZATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNDROME X; VASCULAR SMOOTH MUSCLE;

EID: 27144494933     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.08.006     Document Type: Review

References (45)

1. 2+ homeostasis in vascular smooth muscle J. Vasc. Res. 32 1995 207-219
2. 2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases and myosin phosphatase Physiol. Rev. 83 2003 1325-1358
3. M. Noda et al. Involvement of Rho in GTPγS-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: Inhibition of phosphatase activity FEBS Lett. 367 1995 246-250
4. N. Wettschureck and S. Offermanns Rho/Rho-kinase-mediated signaling in physiology and pathophysiology J. Mol. Med. 80 2002 629-638
5. S. Etienne-Manneville and A. Hall Rho GTPases in cell biology Nature 420 2002 629-635
6. A. Schmidt and A. Hall Guanine nucleotide exchange factors for Rho GTPases: Turning on the switch Genes Dev. 16 2002 1587-1609
7. K.L. Rossman and J. Sondek Larger than Dbl: New structural insights into RhoA activation Trends Biochem. Sci. 30 2005 163-165
8. S. Fukuhara et al. RGS-containing RhoGEFs: The missing link between transforming G proteins and Rho? Oncogene 20 2001 1661-1668
9. α13 Science 280 1998 2112-2114
10. Q. Wang et al. Thrombin and lysophosphatidic acid receptors utilize distinct RhoGEFs in prostate cancer cells J. Biol. Chem. 279 2004 28831-28834
11. 11 J. Biol. Chem. 278 2003 28743-28749
12. M. Amano et al. Regulation and functions of Rho-associated kinase Exp. Cell. Res. 261 2000 44-51
13. T. Matsui et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP-binding protein Rho EMBO J. 15 1996 2208-2216
14. M. Uehata et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 1997 990-994
15. 2α-induced contraction of rabbit aortae J. Physiol. 546 2003 823-836
16. E. VanBavel et al. Role of Rho-associated protein kinase in tone and calcium sensitivity of cannulated rat mesenteric small arteries Exp. Physiol. 86 2001 585-592
17. K. Buyukafsar et al. Rho-kinase expression and its contribution to the control of perfusion pressure in the isolated rat mesenteric vascular bed Eur. J. Pharmacol. 485 2004 263-268
18. 2+ handling of human small arteries Am. J. Physiol. Heart Circ. Physiol. 279 2000 H1228-H1238
19. L. Miao et al. Mechanism of RhoA/Rho-kinase activation in endothelin-1-induced contraction in rabbit basilar artery Am. J. Physiol. Heart Circ. Physiol. 283 2002 H983-H989
20. 2+ Circ. Res. 88 2001 1283-1290
21. L.J. Janssen et al. Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho-kinase Am. J. Physiol. Lung Cell. Mol. Physiol. 280 2001 L666-L674
22. P. Ghisdal et al. Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries J. Physiol. 551 2003 855-867
23. Y. Mukai et al. Involvement of Rho-kinase in hypertensive vascular disease: A novel therapeutic target in hypertension FASEB J. 15 2001 1062-1064
24. K. Ito et al. RhoA/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: Possible involvement in neural mechanisms of hypertension Circ. Res. 92 2003 1337-1343
25. H. Shimokawa et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo Cardiovasc. Res. 51 2001 169-177
26. M. Higashi et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system Circ. Res. 93 2003 767-775
27. T. Seko et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle Circ. Res. 92 2003 411-418
28. N. Moriki et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats Hypertens. Res. 27 2004 263-270
29. Z. Ying et al. Increased expression of mRNA for regulator of G-protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats Am. J. Hypertens. 17 2004 981-985
30. A. Masumoto et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans Hypertension 38 2001 1307-1310
31. A. Masumoto et al. Suppression of coronary artery spasm by a Rho-kinase inhibitor fasudil in patients with vasospastic angina Circulation 105 2002 1545-1547
32. M. Mohri et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with angina and normal coronary angiograms J. Am. Coll. Cardiol. 41 2003 15-19
33. H. Shimokawa et al. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: A multicenter study J. Cardiovasc. Pharmacol. 39 2002 319-327
34. K. Inokuchi et al. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery J. Cardiovasc. Pharmacol. 44 2004 275-277
35. T. Kishi et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure Circulation 111 2005 2741-2747
36. N. Ono-Saito et al. H-series protein kinase inhibitors and potential clinical applications Pharmacol. Ther. 82 1999 123-131
37. H. Tanaka et al. Novel vascular relaxant, Hmn-1152: Its molecular mechanism of action Naunyn-Schmiedeberg's Arch. Pharmacol. 358 1998 p. 3740
38. Y. Sasaki et al. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway Pharmacol. Ther. 93 2002 225-232
39. S.P. Davies et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 351 2000 95-105
40. C. Breitenlechner et al. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: Structural basis of selectivity Structure 11 2003 1595-1607
41. D.A. Anichkov et al. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome Curr. Med. Res. Opin. 21 2005 113-119
42. G. Bonner and W. Fuchs Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension Curr. Med. Res. Opin. 20 2004 597-602
43. C. Calvo et al. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension J. Hypertens. 22 2004 837-846
44. W.B. White et al. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension Am. J. Hypertens. 16 2003 739-745
45. N. Toda Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics Pharmacol. Ther. 100 2003 215-234